Your browser doesn't support javascript.
loading
Mechanisms underlying age-associated exacerbation of pulmonary veno-occlusive disease.
Prabhakar, Amit; Wadhwa, Meetu; Kumar, Rahul; Ghatpande, Prajakta; Gandjeva, Aneta; Tuder, Rubin M; Graham, Brian B; Lagna, Giorgio; Hata, Akiko.
Afiliação
  • Prabhakar A; Cardiovascular Research Institute.
  • Wadhwa M; Department of Anesthesia and Perioperative Care, and.
  • Kumar R; Department of Radiology, UCSF, San Francisco, California, USA.
  • Ghatpande P; Lung Biology Center, Pulmonary and Critical Care Medicine, Zuckerberg San Francisco General Hospital, California, USA.
  • Gandjeva A; Cardiovascular Research Institute.
  • Tuder RM; Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado, USA.
  • Graham BB; Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado, USA.
  • Lagna G; Lung Biology Center, Pulmonary and Critical Care Medicine, Zuckerberg San Francisco General Hospital, California, USA.
  • Hata A; Cardiovascular Research Institute.
JCI Insight ; 9(19)2024 Sep 05.
Article em En | MEDLINE | ID: mdl-39269983
ABSTRACT
Pulmonary veno-occlusive disease (PVOD) is a rare but severe form of pulmonary hypertension characterized by the obstruction of pulmonary arteries and veins, causing increased pulmonary artery pressure and leading to right ventricular (RV) heart failure. PVOD is often resistant to conventional pulmonary arterial hypertension (PAH) treatments and has a poor prognosis, with a median survival time of 2-3 years after diagnosis. We previously showed that the administration of a chemotherapy agent mitomycin C (MMC) in rats mediates PVOD through the activation of the eukaryotic initiation factor 2 (eIF2) kinase protein kinase R (PKR) and the integrated stress response (ISR), resulting in the impairment of vascular endothelial junctional structure and barrier function. Here, we demonstrate that aged rats over 1 year exhibit more severe vascular remodeling and RV hypertrophy than young adult rats following MMC treatment. This is attributed to an age-associated elevation of basal ISR activity and depletion of protein phosphatase 1, leading to prolonged eIF2 phosphorylation and sustained ISR activation. Pharmacological blockade of PKR or ISR mitigates PVOD phenotypes in both age groups, suggesting that targeting the PKR/ISR axis could be a potential therapeutic strategy for PVOD.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pneumopatia Veno-Oclusiva Limite: Animals / Humans / Male Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pneumopatia Veno-Oclusiva Limite: Animals / Humans / Male Idioma: En Ano de publicação: 2024 Tipo de documento: Article